{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:32:44Z","timestamp":1790641964540,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ophtha.2012.01.022","type":"journal-article","created":{"date-parts":[[2012,3,17]],"date-time":"2012-03-17T13:15:39Z","timestamp":1331990139000},"page":"1184-1189","source":"Crossref","is-referenced-by-count":90,"title":["Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study"],"prefix":"10.1016","volume":"119","clinical-trial-number":[{"clinical-trial-number":"nct00906685","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David L.J.","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peep V.","family":"Algvere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunvor","family":"von Wendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Seregard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Kvanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2012.01.022_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(14)70001-7","article-title":"Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics","volume":"117","author":"Hayreh","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006982-200110000-00002","article-title":"Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases","volume":"21","author":"Opremcak","year":"2001","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2012.01.022_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00417-004-1046-0","article-title":"Vitrectomy and radial optic neurotomy for central retinal vein occlusion: effects on visual acuity and macular anatomy","volume":"243","author":"Zambarakji","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/bjo.84.6.609","article-title":"Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study","volume":"84","author":"Glacet-Bernard","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib6","first-page":"219","article-title":"Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion","volume":"99","author":"Elman","year":"2001","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2012.01.022_bib7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/112067210601600609","article-title":"Long-term visual outcomes of vitrectomy for cystoid macular edema due to nonischemic central retinal vein occlusion","volume":"16","author":"Furukawa","year":"2006","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/112067219400400306","article-title":"Macular grid photocoagulation in persistent macular edema due to central retinal vein occlusion","volume":"4","author":"Glacet-Bernard","year":"1994","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0161-6420(95)30848-2","article-title":"A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report","volume":"102","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.01.022_bib10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.01.022_bib12","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2012.01.022_bib13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.01.022_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5301\/EJO.2011.6522","article-title":"Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial","volume":"21","author":"Algvere","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2009.173732","article-title":"Results of bevacizumab as the primary treatment for retinal vein occlusions","volume":"94","author":"Figueroa","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib18","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.01.022_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.01.022_bib20","first-page":"3","article-title":"Lucentis (ranibizumab) [package insert]","year":"2011"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642012000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642012000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T13:35:32Z","timestamp":1561469732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642012000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0161642012000474"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2012.01.022","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}